CoChat

Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

Markovà, Jolana, Essner, Ute, Akmaz, Bülent, Marinelli, Marcella, Trompke, Christiane, Lentschat, Arnd, Vila, Carlos · 2019 · International Journal of Neuroscience

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

) as add-on therapy to optimised standard antispasticity treatment in patients with moderate to severe multiple sclerosis (MS) spasticity. METHODS: as add-on therapy vs. further optimised first-line ANTispastics (SAVANT) was a two-phase trial. In Phase A, eligible patients received add-on THC:CBD spray for 4 weeks to identify initial responders [≥20% improvement from baseline in spasticity 0-10 numerical rating scale (NRS) score]. Following washout, eligible initial responders were randomised to receive THC:CBD spray or placebo for 12 weeks (double-blinded, Phase B). Optimisation of underlying antispasticity medications was permitted in both groups across all study periods. RESULTS: Of 191 patients who entered Phase A, 106 were randomised in Phase B to receive add-on THC:CBD spray (n = 53) or placebo (n = 53). The proportion of clinically relevant responders after 12 weeks (≥30% NRS improvement; primary efficacy endpoint) was significantly greater with THC:CBD spray than placebo (77.4 vs. 32.1%; p < 0.0001). Compared with placebo, THC:CBD spray also significantly improved key secondary endpoints: changes in mean spasticity NRS (p < 0.0001), mean pain NRS (p = 0.0013), and mean modified Ashworth's scale (p = 0.0007) scores from Phase B baseline to week 12. Adverse events, when present, were mild/moderate and without new safety concerns. CONCLUSIONS: Add-on THC:CBD oromucosal spray provided better and clinically relevant improvement of resistant MS spasticity compared with adjusting first-line antispasticity medication alone.

Overview

Integrity signals

Registry

Crossref · 10.1080/00207454.2018.1481066

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 26 references

Cited by

See all 151

Metadata

Authors
Markovà, J., Essner, U., Akmaz, B., Marinelli, M., Trompke, C., Lentschat, A., & Vila, C.
Affiliations
  • Neurology Department, Thomayer's Hospital, Praha, Czechia;
  • O. Meany Consultancy GmbH, Hamburg, Germany;
  • Almirall (Germany) (DE)
  • Almirall (Spain) (ES)
Venue
International Journal of Neuroscience
Published
2018-09-13
Volume
129
Issue
2
Pages
119-128
ISSN
  • 0020-7454 (ISSN-L)
  • 1543-5245
OpenAlex
W2803556125
Cited by
151
References
26
Citations by year
2026: 12 · 2025: 4 · 2024: 21 · 2023: 19 · 2022: 40 · 2021: 22 · 2020: 25 · 2019: 8
FWCI
9.34
Type
journal article
Language
en
Open access
closed
Locations
  • International Journal of Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
Funders
Almirall Hermal GmbH and Almirall S.A.
Topics
  • Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
Sativex, multiple sclerosis, spasticity, adjunctive therapy, pain, Ashworth scale
MeSH terms
Cannabidiol, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Muscle Spasticity, Parasympatholytics, Prospective Studies, Dronabinol, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. https://app.cochat.ai/papers/10.1080/00207454.2018.1481066
The paper
Markovà, J., Essner, U., Akmaz, B., Marinelli, M., Trompke, C., Lentschat, A., & Vila, C. (2019). Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. International Journal of Neuroscience. https://doi.org/10.1080/00207454.2018.1481066

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.